Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor
JCI Insight · 22.04.2026 · 11 (8)
DOI: 10.1172/jci.insight.201148 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 03.03.2026. Verfasst von Kyle D Medak und 14 weiteren Autor:innen. Beteiligte Einrichtung: Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor, Muscle, Smooth, Vascular, Blood Pressure, Glucagon-Like Peptides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, CIHR.
Abstract (Originalsprache)
GLP-1 receptor (GLP-1R) agonists decrease blood glucose and body weight and reduce rates of cardiovascular and renal disease. Although GLP-1R activation lowers blood pressure (BP), the underlying mechanisms remain incompletely understood and have been attributed to weight loss and endothelial cell GLP-1R signaling. Here, we show that GLP-1Rs in vascular smooth muscle cells (VSMCs) are essential for semaglutide-mediated BP reduction in mice. In contrast, GLP-1Rs in Tie2 + endothelial or immune cells are not required for semaglutide to lower BP. The VSMC GLP-1R is dispensable for the effects of semaglutide on food intake, body weight, and blood glucose but is required for its actions to increase glomerular filtration rate and promote natriuresis. Systemic semaglutide administration resulted in proteomic changes in the renal artery and kidney in pathways related to platelet aggregation, fibrin clot formation, lipid metabolism, and proapoptotic signaling that are abolished in mice lacking VSMC GLP-1R expression. Moreover, semaglutide directly induced vasorelaxation in preconstricted mesenteric arteries ex vivo. Together, these findings identify VSMCs as a key cellular target linking GLP-1R activation to BP regulation, renal electrolyte excretion, and proteomic changes in renal artery and kidney.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
- Section of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Förderung
- NHLBI NIH HHS
- CIHR
Zitieren
APA
Medak, K. D., Koehler, J. A., Baggio, L. L., Gonzalez-Rellan, M. J., Wong, C. K., Cao, X., Rao, V., Kao, S., Cui, Y., Fu, J., Liaw, E., Kabir, M. G., Zhang, J., Wei, J., & Drucker, D. J. (2026). Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor. JCI Insight, 11(8). https://doi.org/10.1172/jci.insight.201148
Vancouver
Medak KD, Koehler JA, Baggio LL, Gonzalez-Rellan MJ, Wong CK, Cao X, et al. Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor. JCI Insight. 2026;11(8). doi:10.1172/jci.insight.201148
BibTeX
@article{Medak2026,
author = {Medak, Kyle D and Koehler, Jacqueline A and Baggio, Laurie L and Gonzalez-Rellan, Maria J and Wong, Chi Kin and Cao, Xiemin and Rao, Vivikta and Kao, Sean and Cui, Yu and Fu, Jiayi and Liaw, Easton and Kabir, M Golam and Zhang, Jie and Wei, Jin and Drucker, Daniel J},
title = {Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor},
journal = {JCI Insight},
year = {2026},
volume = {11},
number = {8},
doi = {10.1172/jci.insight.201148}
}
EUVIMED